Thrombosis

Test for blood clots enters ongoing multicenter clinical trial

Published in Blood Weekly, November 14th, 2002

IGEN International, Inc., (IGEN) announced that its proprietary test for the diagnosis of venous thromboembolic (VTE) disease, commonly known as blood clots, will be used in an ongoing multicenter clinical trial sponsored by Canadian Institutes of Health Research (CIHR).

The study will test for the presence of urinary fibrinopeptide B (FPB) as a marker for active VTE, as well as a tool to monitor the effectiveness of anticoagulant therapy. Preliminary studies and data have confirmed that urine FPB levels can be used to screen patients with suspected VTE and to monitor patients following treatment.

The company has exclusive commercialization rights...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2002-11-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry